All In Biotech

Drug Trial Radar · NCT00002772

S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

A Comparison of Intensive Sequential Chemotherapy Using Doxorubicin Plus Paclitaxel Plus Cyclophosphamide With High Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Support for Primary Breast Cancer in Women With 4-9 Involved Axillary Lymph Nodes

Last checked: Nov 19, 2026Latest source record: Jan 24, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 602 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

602

Actual

Start

Jul 1996

Primary completion

Feb 2004

Study completion Feb 2004

Sponsor

Lead sponsor
SWOG Cancer Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Cancer and Leukemia Group B
First posted
Apr 22, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which regimen of chemotherapy followed by peripheral stem cell transplantation is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating women who have undergone surgery for breast cancer.

Conditions

  • Breast Cancer

Interventions

  • filgrastimBiological

  • carboplatinDrug

  • carmustineDrug

  • cisplatinDrug

  • cyclophosphamideDrug

  • doxorubicin hydrochlorideDrug

  • paclitaxelDrug

  • tamoxifen citrateDrug

  • thiotepaDrug

  • autologous bone marrow transplantationProcedure

  • peripheral blood stem cell transplantationProcedure

  • radiation therapyRadiation

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.